Clinical trial · Interventional
Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection
Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection-Single Center Phase II Single Arm Clinical Trial
NCT06189183CI-TRIAL-00114863active not recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the efficiency and toxicity of adjuvant hypofractionation radiotherapy for thymic epithelial tumours after complete resection.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thymus Neoplasms | Thymus Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Adjuvant Hypofractionation Radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Adjuvant Hypofractionation Radiotherapy
- description
- Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection
- interventionNames
- Radiation: Adjuvant Hypofractionation Radiotherapy
Primary outcomes (1)
- measure
- Disease Free Survival
- timeFrame
- 2 years, 5 years
- description
- From the date of resection to the date of disease recurrence or death
Secondary outcomes (5)
- measure
- Overall Survival
- timeFrame
- 2 years, 5 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Thymoma and Thymic carcinoma confirmed by histology or cytology * R0 resection (complete resection) * stage II and III thymic carcinoma，stage III thymoma，stage IIB B2/B3 thymomas. * Karnofsky performance status(KPS) 80, 90 or 100. * Having sufficient Pulmonary function, renal function and liver function. Neutrophile granulocyte count\>1.5×109 /L, platelet count\>80×109 /L, hemoglobin ≥10g/dL. Exclusion Criteria: * Prior thoracic radiotherapy. * Uncontrolled Comorbidities. * Pregnant or nursing mother. * Pneumonia
References
Publications (0)
Data not yet available
No reference posted for this study.